Engineered Blood Vessel Outperforms Standard Dialysis Access in Women
A Phase 3 trial shows Humacyte's lab-grown vessel delivers 220 catheter-free days vs 129 for standard fistulas in dialysis patients.
Summary
A lab-grown blood vessel developed by Humacyte significantly outperformed the standard surgical option for women on kidney dialysis in a Phase 3 clinical trial. The acellular tissue-engineered vessel (ATEV) gave patients an average of 220 catheter-free days in the first year, compared to just 129 days for the conventional arteriovenous fistula. Infection rates were dramatically lower — about 6 infections per 100 patient-years versus 23 for the fistula group. No vessel-linked infections or ruptures occurred in the ATEV group. These results spanned multiple secondary endpoints, including better patency and fewer serious adverse events. Humacyte plans to file for FDA approval in late 2026, targeting patients at high risk of fistula failure — a common and serious complication in chronic kidney disease management.
Detailed Summary
Kidney disease patients on dialysis depend on reliable vascular access to sustain their lives, and when that access fails, the consequences are serious. A new Phase 3 trial from Humacyte suggests a lab-engineered alternative to the surgical gold standard may offer a major leap forward — especially for women, who face higher rates of fistula maturation failure.
The trial compared Humacyte's acellular tissue-engineered vessel (ATEV) against the conventional arteriovenous fistula in women undergoing dialysis. The primary outcome — catheter-free days in the first year — strongly favored the ATEV: 220 days versus 129 days, a statistically significant result. This matters enormously because prolonged catheter use is associated with life-threatening bloodstream infections and reduced quality of life.
Secondary endpoints reinforced the finding. At six months, ATEV patients averaged 88 catheter-free days versus just 32. Functional patency — meaning the access point remained usable — lasted 250 days for ATEV compared to 152 for fistulas. Six-month secondary patency rates were 87.5% versus 65%. Critically, infection rates were nearly four times lower with the engineered vessel, and no ATEV-linked vessel infections occurred.
The ATEV is acellular, meaning it contains no living donor cells, which reduces immune rejection risk and may explain the lower infection profile. This bioengineered approach represents a meaningful convergence of regenerative medicine and vascular surgery — relevant not just for dialysis but potentially for broader vascular repair applications.
Caveats include that the trial focused specifically on women, a population known to struggle with fistula maturation, so results may not generalize to all dialysis patients. The trial is also a news-reported summary rather than a peer-reviewed publication. Humacyte intends to file a supplemental biologics license application with the FDA in the second half of 2026.
Key Findings
- ATEV delivered 220 catheter-free days in year one vs 129 for standard fistula in women on dialysis.
- Infection rates were nearly 4x lower with the engineered vessel: 6 vs 23 per 100 patient-years.
- No ATEV-linked vessel infections or ruptures occurred throughout the trial.
- Six-month functional patency strongly favored ATEV (88 vs 32 catheter-free days, p=0.00009).
- Humacyte plans FDA supplemental biologics filing in late 2026 for high-risk fistula failure patients.
Methodology
This is a news report summarizing Phase 3 clinical trial results presented at a major vascular surgery conference. The source, Longevity.Technology, covers medical research but this is not a peer-reviewed publication. Statistical significance was reported with p-values, suggesting rigorous trial design, though full methodology requires review of the primary publication.
Study Limitations
Results apply specifically to women on dialysis and may not generalize to male patients or other populations. Data are from a conference presentation, not yet peer-reviewed or published in full. Long-term durability and cost-effectiveness of the ATEV compared to fistulas remain to be established.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.